Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Abstract: Hepatic toxicity is the most serious adverse effect of anti-tuberculosis drugs. This study was performed to evaluate the efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial, 70 new cases of pulmonary tuberculosis were divided into two group...

Descripción completa

Detalles Bibliográficos
Autores principales: Marjani, Majid, Baghaei, Parvaneh, Kazempour Dizaji, Mehdi, Gorji Bayani, Pegah, Fahimi, Fanak, Tabarsi, Payam, Velayati, Ali Akbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986122/
https://www.ncbi.nlm.nih.gov/pubmed/27610165
_version_ 1782448154049773568
author Marjani, Majid
Baghaei, Parvaneh
Kazempour Dizaji, Mehdi
Gorji Bayani, Pegah
Fahimi, Fanak
Tabarsi, Payam
Velayati, Ali Akbar
author_facet Marjani, Majid
Baghaei, Parvaneh
Kazempour Dizaji, Mehdi
Gorji Bayani, Pegah
Fahimi, Fanak
Tabarsi, Payam
Velayati, Ali Akbar
author_sort Marjani, Majid
collection PubMed
description Abstract: Hepatic toxicity is the most serious adverse effect of anti-tuberculosis drugs. This study was performed to evaluate the efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial, 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment.
format Online
Article
Text
id pubmed-4986122
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-49861222016-09-08 Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial Marjani, Majid Baghaei, Parvaneh Kazempour Dizaji, Mehdi Gorji Bayani, Pegah Fahimi, Fanak Tabarsi, Payam Velayati, Ali Akbar Iran J Pharm Res Original Article Abstract: Hepatic toxicity is the most serious adverse effect of anti-tuberculosis drugs. This study was performed to evaluate the efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial, 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment. Shaheed Beheshti University of Medical Sciences 2016 /pmc/articles/PMC4986122/ /pubmed/27610165 Text en © 2016 by School of Pharmacy, Shaheed Beheshti University of Medical Sciences and Health Services This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Marjani, Majid
Baghaei, Parvaneh
Kazempour Dizaji, Mehdi
Gorji Bayani, Pegah
Fahimi, Fanak
Tabarsi, Payam
Velayati, Ali Akbar
Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
title Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
title_full Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
title_fullStr Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
title_full_unstemmed Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
title_short Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
title_sort evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986122/
https://www.ncbi.nlm.nih.gov/pubmed/27610165
work_keys_str_mv AT marjanimajid evaluationofhepatoprotectiveeffectofsilymarinamongundertreatmenttuberculosispatientsarandomizedclinicaltrial
AT baghaeiparvaneh evaluationofhepatoprotectiveeffectofsilymarinamongundertreatmenttuberculosispatientsarandomizedclinicaltrial
AT kazempourdizajimehdi evaluationofhepatoprotectiveeffectofsilymarinamongundertreatmenttuberculosispatientsarandomizedclinicaltrial
AT gorjibayanipegah evaluationofhepatoprotectiveeffectofsilymarinamongundertreatmenttuberculosispatientsarandomizedclinicaltrial
AT fahimifanak evaluationofhepatoprotectiveeffectofsilymarinamongundertreatmenttuberculosispatientsarandomizedclinicaltrial
AT tabarsipayam evaluationofhepatoprotectiveeffectofsilymarinamongundertreatmenttuberculosispatientsarandomizedclinicaltrial
AT velayatialiakbar evaluationofhepatoprotectiveeffectofsilymarinamongundertreatmenttuberculosispatientsarandomizedclinicaltrial

Ejemplares similares